Background T e immune system can eliminate cancer, so strategies to increase antitumor
immunity have emerged as a primary therapeutic approach for the treatment of melanoma.
While the immune system is complex and multifaceted, therapeutic approaches to antitumor
immunity have largely focused on T cells. T-cell immunity is controlled by immune
checkpoints. T ese are physiologic on/off switches that enable immune responses to
potentially threatening antigens, while protecting the host from overzealous immune …